Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
770 participants
INTERVENTIONAL
2024-06-01
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be randomized into 2 study arms (385 participant each), whereby:
* The Metformin Group (MG): will receive metformin oral tablets in addition to the standard rate/rhythm control strategy and anticoagulation.
* The Placebo Control Group (PCG): will receive placebo oral tablets as a control group in addition to the standard rate/rhythm control strategy and anticoagulation.
Then both arms will be compared according to the these endpoints:
* The primary endpoint is hospitalization due to an episodic AF or an AF with a rapid or slow ventricular response (in the case of permanent AF).
* The secondary endpoint is a composite of non-fatal major cardiovascular adverse events or non-cancer death.
The non-fatal major cardiovascular adverse events include:
* Hospitalization due to heart failure.
* Non-fatal myocardial infarction.
* Non-fatal stroke.
* Hospitalization due to unstable angina.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metformin as an Upstream Therapy in Atrial Fibrillation
NCT02931253
Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation
NCT04625946
Atrial Fibrillation and Diabetes Mellitus
NCT05873920
Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)
NCT03603912
Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation
NCT06111443
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Therapeutic Area: Cardiology, Arrhythmia.
* Purpose: Treatment.
* Aim: Whether repurposing metformin for the treatment of atrial fibrillation will be effective in decreasing patients' hospitalization, adverse major cardiovascular events, and non-cancer death.
* Assignment: Parallel.
* Allocation: Randomized.
* Masking: Pragmatic, Open-Label.
* Duration: 12 months of follow-up.
* Rationale: Atrial fibrillation (AF) is the most common heart arrhythmia \[1\], in which atria contract rapidly and irregularly and the contraction of atria and ventricles is no longer coordinated. Current guidelines for the treatment of AF recommend medication to avoid blood clotting and stroke, control heart rate, and restore sinus rhythm. However, the available treatments show limited efficiency and may have side effects associated with increased morbidity and mortality \[2\], emphasizing an urgent need for new or repurposed therapies. Lal and colleagues \[3\] reported an integrative approach-combining transcriptomics, iPSCs, and epidemiological evidence-to identify and repurpose metformin, a main first-line medication for the treatment of type 2 diabetes, as an effective risk reducer for atrial fibrillation. Interestingly, metformin enhances the life span in invertebrate and vertebrate laboratory models \[4\], and similar gene-expression-based drug-repurposing studies targeting aging identified metformin, among others, as a pro-longevity agent \[5\]. Diabetes and AF are both age-associated and often co-morbid conditions. Metformin is being tested in the Targeting Aging with Metformin (TAME) trial \[6\] to develop effective next-generation drugs to increase healthspan and lifespan. Additionally, metformin seems to be associated with a lower risk of atrial fibrillation and ventricular arrhythmias as compared with another anti-diabetic drug category which is sulfonylureas \[7\]. The potential antiarrhythmic role of metformin in patients with AF could be due to the effects of metformin on preventing the structural and electrical remodeling of the left atrium via attenuating intracellular reactive oxygen species, activating 5' adenosine monophosphate-activated protein kinase, improving calcium homeostasis, attenuating inflammation, increasing connexin-43 gap junction expression, and restoring small conductance calcium-activated potassium channels current \[8\]. Despite the solid preclinical, integrative, and retrospective analyses, the effect of metformin on patients with AF regarding morbidity and mortality has not be established using a perspective, randomized, controlled trial.
* Inclusion Criteria: Age more than 20 years and less than 65 years, willing and able to provide written informed consent prior to performing study procedures, and diagnosed by atrial fibrillation (first detected, paroxysmal, persistent, longstanding persistent, or permanent).
* Exclusion Criteria: Critically-ill patients who are admitted to ICU, advanced congestive heart failure, liver cell failure, chronic kidney disease with eGFR \<45 mL/min/1.73 m², diabetic ketoacidosis with or without coma, concomitant treatment with carbonic anhydrase inhibitors, septicemia, shock, hypoxia, dehydration, blood dyscrasias, pregnancy, lactation, chronic muscle diseases, acute trauma or burns within 2 weeks, and history of allergy to the implemented drugs.
* Methods: 770 enrolled AF patients who are candidates for metformin treatment according to the study criteria at the time of presentation, will undergo the following at the time of enrollment and during the bimonthly follow-ups:
* General and Local cardiac examination.
* CBC.
* Chemistry Panel including KFTs, LFTs.
* Serum electrolytes levels.
* Resting surface 12 leads ECG.
* Baseline echocardiography.
* Interventions:
* Drug: metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.
Other Name: Glucophage.
* Drug: Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. Other Name: Placebo
\- Study Arms:
* The Metformin Group (MG): 385 patients will receive metformin oral tablets in addition to the standard rate/rhythm control strategy and anticoagulation.
* The Placebo Control Group (PCG): 385 patients will receive placebo oral tablets as a control group in addition to the standard rate/rhythm control strategy and anticoagulation.
Endpoints:
* The primary endpoint is hospitalization due to an episodic AF or an AF with a rapid or slow ventricular response (in the case of permanent AF).
* The secondary endpoint is a composite of non-fatal major cardiovascular adverse events or non-cancer death.
The non-fatal major cardiovascular adverse events include:
* Hospitalization due to heart failure.
* Non-fatal myocardial infarction.
* Non-fatal stroke.
* Hospitalization due to unstable angina.
• Safety: In terms of safety, a composite of metformin side effects comprising GIT symptoms, hypoglycemia, and lactic acidosis will be considered.
* Ethics: The study will be conducted in compliance with human studies committees' regulations of the authors' institutions and COPE guidelines, including patient consent as appropriate.
* Competing Interests: The authors will declare any commercial or financial relationships that could be construed as a potential conflict of interest.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The Metformin Group (MG)
The group (n=385) will receive metformin oral tablets in addition to the standard rate/rhythm control strategy and anticoagulation.
• Drug: metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.
Other Name: Glucophage.
Metformin
Metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.
The Placebo Control Group (PCG)
The group (n=385) will receive placebo oral tablets in addition to the standard rate/rhythm control strategy and anticoagulation.
• Drug: Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. Other Name: Placebo
Placebo
Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metformin
Metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.
Placebo
Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Atrial fibrillation (first detected, paroxysmal, persistent, longstanding persistent, or permanent)\*.
\* Types of atrial fibrillation:
* First detected: only one diagnosed episode.
* Paroxysmal: recurrent episodes that stop on their own in less than seven days.
* Persistent: recurrent episodes that last more than seven days.
* Longstanding persistent: recurrent episodes that last more than twelve months.
* Permanent: atrial fibrillation that has been accepted, and for which a solely rate control strategy has been decided upon.
Exclusion Criteria
* Advanced congestive heart failure.
* Liver cell failure.
* Chronic kidney disease with eGFR \<45 mL/min/1.73 m².
* Diabetic ketoacidosis with or without coma.
* Concomitant treatment with carbonic anhydrase inhibitors.
* Septicemia.
* Shock.
* Hypoxia.
* Dehydration.
* Blood Dyscrasias.
* Alcoholism.
* Pregnancy.
* Lactation.
* Chronic muscle diseases.
* Acute trauma or burns within 2 weeks.
* History of allergy to the implemented drugs.
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arab Contractors Medical Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eslam Abbas, MBChB, MSc
Principal Invstigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eslam Abbas, MBBCh, MSC
Role: PRINCIPAL_INVESTIGATOR
Arab Contractors Medical Centre, and Dar El Salam Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arab Contractors Medical Centre
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA, Noseworthy PA, Pack QR, Sanders P, Trulock KM; American Heart Association Electrocardiography and Arrhythmias Committee and Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Lifestyle and Cardiometabolic Health. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. Circulation. 2020 Apr 21;141(16):e750-e772. doi: 10.1161/CIR.0000000000000748. Epub 2020 Mar 9.
Schwaerzer G. Repurposing metformin for treatment of atrial fibrillation. Nat Cardiovasc Res. 2022 Nov;1(11):972. doi: 10.1038/s44161-022-00170-1. No abstract available.
Lal JC, Mao C, Zhou Y, Gore-Panter SR, Rennison JH, Lovano BS, Castel L, Shin J, Gillinov AM, Smith JD, Barnard J, Van Wagoner DR, Luo Y, Cheng F, Chung MK. Transcriptomics-based network medicine approach identifies metformin as a repurposable drug for atrial fibrillation. Cell Rep Med. 2022 Oct 18;3(10):100749. doi: 10.1016/j.xcrm.2022.100749. Epub 2022 Oct 11.
Vinciguerra M, Olier I, Ortega-Martorell S, Lip GYH. New use for an old drug: Metformin and atrial fibrillation. Cell Rep Med. 2022 Dec 20;3(12):100875. doi: 10.1016/j.xcrm.2022.100875.
Donertas HM, Fuentealba Valenzuela M, Partridge L, Thornton JM. Gene expression-based drug repurposing to target aging. Aging Cell. 2018 Oct;17(5):e12819. doi: 10.1111/acel.12819. Epub 2018 Aug 9.
Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a Tool to Target Aging. Cell Metab. 2016 Jun 14;23(6):1060-1065. doi: 10.1016/j.cmet.2016.05.011.
Ostropolets A, Elias PA, Reyes MV, Wan EY, Pajvani UB, Hripcsak G, Morrow JP. Metformin Is Associated With a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas: An Observational Study. Circ Arrhythm Electrophysiol. 2021 Mar;14(3):e009115. doi: 10.1161/CIRCEP.120.009115. Epub 2021 Feb 7.
Nantsupawat T, Wongcharoen W, Chattipakorn SC, Chattipakorn N. Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient. Cardiovasc Diabetol. 2020 Nov 24;19(1):198. doi: 10.1186/s12933-020-01176-4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
#18101829
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.